In the NAFLD-Biopsy subset, for subjects with T2DM, with or without obesity, all characteristics were different vs. subjects without T2DM and non-obese (controls), except for ApoA1 level and NASH prevalence. Here, APOA1 is linked to metabolic dysfunction-associated steatotic liver disease.